sinc
decemb
outbreak
new
coronaviru
name
greatli
threaten
public
health
china
rais
great
concern
worldwid
specif
treatment
infect
current
avail
previous
report
teicoplanin
glycopeptid
antibiot
routin
use
clinic
treat
bacteri
infect
low
toxic
significantli
inhibit
invas
cell
ebola
viru
sarscov
merscov
via
specif
inhibit
activ
cathepsin
l
test
efficaci
teicoplanin
viru
infect
found
teicoplanin
potent
prevent
entranc
cytoplasm
ic
although
inhibitori
effect
upon
replic
wildtyp
virus
ex
vivo
vivo
remain
determin
preliminari
result
indic
potenti
antivir
activ
teicoplanin
could
appli
treatment
viru
infect
coronavirus
envelop
posit
sens
singlestrand
rna
spike
glycoprotein
protein
lead
mediat
viral
entri
import
determin
host
rang
coronavirus
infect
sar
viru
initi
attach
protein
receptor
follow
cleavag
host
cell
proteas
virus
transport
earli
late
endosom
subsequ
endolysosom
host
protein
extracellular
proteas
includ
cathepsin
l
mediat
cleavag
protein
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
endocyt
vesicl
activ
protein
activ
fusion
viral
cell
membran
releas
genom
sarscov
cytoplasm
team
found
teicoplanin
routinelyus
clinic
glycopeptid
antibiot
significantli
inhibit
cellular
entri
ebola
viru
sarscov
merscov
mechanist
studi
show
teicoplanin
block
viru
entri
specif
inhibit
activ
cathepsin
l
open
novel
avenu
develop
glycopeptid
potenti
inhibitor
cathepsin
ldepend
virus
studi
compar
cleavag
site
cathepsin
l
sarscov
found
well
conserv
furthermor
identifi
teicoplanin
also
potent
inhibit
entri
pseudoviru
provid
possibl
strategi
prophylaxi
treatment
infect
plasmid
contain
spike
gene
purchas
generay
biotech
compani
shanghai
china
insert
vector
pseudovirus
produc
cotransfect
phivluciferas
plasmid
express
differ
envelop
protein
cell
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
previous
describ
sequenc
data
collect
align
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
genom
sequenc
sarscov
collect
genbank
databas
http
wwwncbinlmnihgovnuccor
consensu
sequenc
creat
use
bioedit
softwar
http
wwwmbioncsuedubioeditbioedithtml
base
multipl
align
sarscov
respect
amino
acid
sequenc
logo
gener
use
weblogo
statist
analysi
perform
graphpad
prism
data
normal
distribut
use
student
test
multipl
comparison
oneway
twoway
anova
parametr
data
follow
bonferroni
correct
two
group
compar
use
p
valu
consid
statist
signific
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
proteolyt
process
sarscov
protein
essenti
moreov
cleavag
site
cathepsin
l
consist
among
epidem
strain
retriev
genbank
databas
includ
wuhan
shenzhen
usa
figur
hypothes
cathepsin
l
could
import
target
entri
accordingli
infect
cell
sarscov
spseudotyp
virus
sirnamedi
knockdown
express
cathepsin
l
found
cathepsin
l
deplet
impair
cell
entri
pseudovirus
figur
indic
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cathepsin
l
requir
cell
entri
base
previou
report
gener
pseudovirus
figur
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
previous
demonstr
sever
glycopeptid
antibiot
includ
teicoplanin
dalbavancin
exhibit
specif
inhibitori
effect
cathepsin
l
therefor
hypothes
teicoplanin
homolog
could
also
inhibit
entri
data
illustr
dalbavancin
also
repress
entri
dosedepend
manner
figur
howev
vancomycin
anoth
routinelyus
antibiot
inhibit
entri
teicoplanin
glycopeptid
antibiot
mainli
use
seriou
infect
caus
gramposit
bacteria
staphylococcu
aureu
streptococcu
routinelyus
clinic
antibiot
teicoplanin
well
known
much
low
toxic
side
effect
long
halflif
blood
plasma
conveni
administr
high
safeti
use
combin
antibiot
recommend
plasma
concentr
teicoplanin
clinic
use
inhibit
gramposit
bacteria
mg
l
commonli
use
dose
mg
day
found
ic
inhibit
much
lower
routin
clinic
drug
concentr
therefor
routinelyus
dose
mg
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
day
could
consid
patient
infect
effect
signific
dose
could
optim
low
toxic
dose
mg
day
mg
day
could
consid
improv
drug
effici
given
principl
antivir
therapi
prevent
viru
infect
amplif
stage
earli
possibl
reason
recommend
use
teicoplanin
potenti
conflict
interest
report
author
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
schema
graph
entri
target
cell
bind
viru
cellular
receptor
proteolyt
process
initi
cellular
membran
virion
uptaken
endosom
protein
activ
cleavag
cystein
proteas
cathepsin
l
cleavag
protein
cathepsin
l
significantli
block
teicoplanin
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
zhou
p
et
al
pneumonia
outbreak
associ
new
coronaviru
probabl
bat
origin
natur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
bosch
b
j
bartelink
w
rottier
p
j
cathepsin
l
function
cleav
sever
acut
respiratori
syndrom
coronaviru
class
fusion
protein
upstream
rather
adjac
fusion
peptid
j
virol
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
